

Falk Symposium

183



# Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy

May 4 – 5, 2012

Congress Center Basel  
Switzerland



## Preliminary Program

**Application for  
CME credits  
submitted**

▶	Preface . . . . .	4
▶	Scientific Program . . . . .	6
▶	Posters . . . . .	10
▶	List of Speakers . . . . .	11
▶	Information . . . . .	15

CME credits for the Falk Symposium 183 have been applied for at the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG). The number of credits awarded will be printed in the final program.

## Preface

Our understanding of the pathogenesis of inflammatory bowel disease has dramatically changed during the last years. The focus of research has shifted from adaptive immunity to genetic risk factors and now to disturbances in innate immunity and the interactions of the mucosal immune system with the content of the gut – our “environment”. The environment is a term introduced by Michael Mayerfeld Bell in his book „An Invitation to Environmental Sociology.“ He describes it as the “human body, which is continuously interacting with the environment”. He points to the fact that eating and drinking are special ways for humans to interact with their environment.

The groundbreaking insights gained in the last years indicate that the genetic factors contribute only less than 50% to the risk to develop IBD. Environmental factors may trigger or even cause the disease. Those factors mediate their effects via uptake into the human body. They may change the composition of our microbiome making it more pro-inflammatory or aggressive. Other factors may directly act on the intestinal barrier function.

Our therapeutic approaches still mainly focus on regulating adaptive immunity. Only recently the barrier function of the gut mucosa and the defense function of the innate immune system have come into focus. The meeting therefore will highlight recent discoveries that may change our future treatment strategies. It seems to be promising to intervene early in the pathogenic process, we only start to understand at present.

In our two day meeting which will offer you latest insights from reknown experts the first day will be reserved for the newest data on pathogenic factors. Genetic risk factors, microbiome changes, helminth effects, barrier functions of the mucosa and environmental risk factors will be highlighted. The second day is focussed on newest developments in IBD therapy. We will discuss the value of new diagnostic markers, the options to change environmental influences, the advantages and disadvantages of classical immunosuppression and the value of new concepts such as mucosal healing and deep remission.

We hope that the program and the outstanding faculty will attract you interest and look forward to meet you in Basel in May 2012.

G. Rogler  
C. Beglinger

J. F. Colombel  
P. Michetti



# Dealing with our „In-vironment“: New Aspects in IBD Pathogenesis and Therapy

Congress Center Basel  
Switzerland

**Registration:**

Thursday, May 3, 2012  
8.00 – 16.30  
at the congress office

**Scientific Organization:**

G. Rogler, Zurich (Switzerland)  
C. Beglinger, Basel (Switzerland)  
J. - F. Colombel, Lille (France)  
P. Michetti, Lausanne (Switzerland)

**Congress Venue:**

Congress Center Basel  
Messeplatz 21  
4058 Basel  
Switzerland

**Information:**

Prof. Dr. Dr. Gerhard Rogler  
Universitätsspital Zürich  
Klinik für Gastroenterologie & Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
Telephone: +41(0)44/255 95 19  
Telefax: +41(0)44/255 94 97  
E-mail: gerhard.rogler@usz.ch

**Official Language:**

English

**Call for posters:**

For details see page 10

**Publication date of final program:**

May 2012

The final program will be available on the homepage [www.falkfoundation.org](http://www.falkfoundation.org) one week before.

# ▶ Friday, May 4, 2012

**8.00** Opening remarks G. Rogler,  
Zurich

## **Session I** **Genetic risk factors in IBD:** **Impaired control of the “in-vironment”?**

**Chair:** D. P. Jewell, Oxford; S. Schreiber, Kiel

**8.10** Risk genes for ulcerative colitis: Role for bacterial homeostasis? R. Duerr,  
Pittsburgh

**8.35** Risk genes in Crohn’s disease: What are the most important pathways affected? A. Franke,  
Kiel

**9.00** The “promise of epigenetics”: Will it deliver new insights? S. Gay,  
Zurich

**9.25 State-of-the-Art Lecture I**  
Genes and “in-vironment”: How will our concepts on the pathophysiology of IBD develop in the future? C. Fiocchi,  
Cleveland

**9.50 Coffee break with poster session**

## **Session II** **IBD: The “in-vironment” out of control?**

**Chair:** C. Fiocchi, Cleveland; R. B. Sartor, Chapel Hill

**10.20** IBD: A defensin deficiency? J. Wehkamp,  
Stuttgart

**10.45** Do bacteria stress the epithelial barrier? A. Kaser,  
Cambridge

**11.10** IBD: Dysfunction of autophagy? M. Scharl,  
Zurich

**11.35** Helminths and epithelial cells J. V. Weinstock,  
Boston

**12.00** Smoking cessation changes the “in-vironment” L. Biedermann,  
Zurich

**12.25 Lunch break with poster session**

**20 minutes lecture 5 minutes discussion**



**Friday, May 4, 2012**

### **Session III**

## **The epithelial barrier as border to the "in-vironment"**

**Chair:** C. Beglinger, Basel; E. F. Stange, Stuttgart

- |              |  |                           |
|--------------|--|---------------------------|
| <b>13.30</b> | Regeneration of the barrier: The role of stem cells        | N. F. Shroyer, Cincinnati |
| <b>13.55</b> | Novel mechanisms of control of epithelial barrier function | S. Danese, Rozzano        |
| <b>14.20</b> | The leaky epithelium in IBD                                | J.-D. Schulzke, Berlin    |
| <b>14.45</b> | PPA-gamma maintains antimicrobial immunity in the colon    | M. Chamailard, Lille      |
| <b>15.10</b> | <b>Coffee break with poster session</b>                    |                           |

### **Session IV**

## **Environment and "in-vironment"**

**Chair:** J. Cosnes, Paris; M. H. Vatn, Oslo

- |              |  |                           |
|--------------|--|---------------------------|
| <b>15.40</b> | Why and where to look in the environment in regards to IBD etiology  | C. N. Bernstein, Winnipeg |
| <b>16.05</b> | Does our food (environment) change our gut microbiome ("in-vironment"): Potential role for IBD?              | P. Lepage, Jouy-en-Josas  |
| <b>16.30</b> | DAMPs (danger associated molecular patterns) and IBD: Is there a connection?                                 | C. Müller, Berne          |
| <b>16.55</b> | Microparticles   | G. Rogler, Zurich         |
| <b>17.20</b> | <b>State-of-the-Art Lecture II</b><br>IBD and "in-vironment": What have we learned during the last 20 years? | R. B. Sartor, Chapel Hill |
| <b>17.50</b> | <b>End of afternoon session</b>  |                           |

**20 minutes lecture 5 minutes discussion**



# Saturday, May 5, 2012

## Session V

### Treatment decisions made easy:

### Do we have the disease markers we need?

**Chair:** M. Fried, Zurich; J. Schölmerich, Frankfurt

- |             |  |                           |
|-------------|--|---------------------------|
| <b>8.00</b> | Circulating antibodies against bacterial wall products: Are there arguments for early immunosuppression? | F. Rieder, Cleveland      |
| <b>8.25</b> | Clinical risk factors for complicated disease: How reliable are they?                                    | L. Peyrin-Biroulet, Nancy |
| <b>8.50</b> | Treatment decision based on biomarkers – An upcoming option?   | C. Beglinger, Basel       |
| <b>9.15</b> | Intestinal absorption and vitamin levels: Is there need for a new focus?                                 | S. Vavricka, Zurich       |
| <b>9.40</b> | <b>Coffee break with poster session</b>  |                           |

## Session VI

### Changing the “in-vironment” for therapy

**Chair:** P. L. Lakatos, Budapest; G. Rogler, Zurich

- |              |   |                         |
|--------------|---|-------------------------|
| <b>10.10</b> | Antibiotics for IBD therapy   | H. Lochs, Innsbruck     |
| <b>10.35</b> | Specific probiotics or “fecal transplantation”?   | W. Kruis, Cologne       |
| <b>11.00</b> | Mucosal protection  | W. Stremmel, Heidelberg |
| <b>11.25</b> | Topical therapy   | V. Gross, Amberg        |
| <b>11.50</b> | <b>State-of-the-Art Lecture III</b><br>The risks and benefits of early immunosuppression and biological therapy | B. E. Sands, New York   |
| <b>12.20</b> | <b>Lunch break with poster session</b>  |                         |

**20 minutes lecture 5 minutes discussion**



# Saturday, May 5, 2012

## Session VII

### The classical immunosuppression: Overrated or underused?

**Chair:** P. Michetti, Lausanne; M. Zeitz, Berlin

- |              |   |                          |
|--------------|---|--------------------------|
| <b>13.30</b> | Mucosal healing: A new treatment goal or old wine in new skins                        | M. Allez, Paris          |
| <b>13.55</b> | Deep remission: A new concept?  | J.-F. Colombel, Lille    |
| <b>14.20</b> | Methotrexate: Underused and ignored?  | H. Herfarth, Chapel Hill |
| <b>14.45</b> | Azathioprine in the post-SONIC era: To combine or not combine – That is the question? | P. Michetti, Lausanne    |
| <b>15.10</b> | Tacrolimus and cyclosporin  | E. F. Stange, Stuttgart  |
| <b>15.35</b> | <b>Coffee break with poster session</b>   |                          |
| <b>16.10</b> | <b>Presentation of poster prizes</b>  | G. Rogler, Zurich,       |

## Session VIII

### Biologicals and beyond

**Chair:** J.-F. Colombel, Lille; O. H. Nielsen, Herlev

- |              |  |                          |
|--------------|--|--------------------------|
| <b>16.20</b> | Biological treatment of Crohn's disease  | W. Reinisch, Vienna      |
| <b>16.45</b> | Biological treatment of ulcerative colitis   | S. Ghosh, Calgary        |
| <b>17.10</b> | Stem cell transplantation: The ASTIC trial   | C. J. Hawkey, Nottingham |
| <b>17.35</b> | Anti-adhesion molecule therapy   | B. G. Feagan, London, ON |
| <b>18.00</b> | <b>State-of-the-Art Lecture IV</b><br>The future of IBD therapy: Where do we go from here? | W. J. Sandborn, La Jolla |
| <b>18.30</b> | Closing remarks  |                          |

## Poster Session

Posters will be exhibited on May 4 – 5, 2012, at the Congress Center Basel. The authors will be in attendance during coffee and lunch breaks on both days.

## Call for posters

Please submit your poster abstract before **January 31, 2012**. Only one-page abstracts not exceeding 250 words, written in English and saved in Microsoft Word format will be accepted.

Abstracts must be submitted via our Internet Abstract Submission System (<http://www.falkfoundation.com/poster>) where further information regarding the submission format and the submission process is available.

The abstracts will be selected by the scientific organizers, preference being given to those thematically related to one of the sessions of the program.

The accepted abstracts will be printed and distributed to the participants of the congress together with the documents of the meeting.

The authors will receive notification about acceptance and further instructions in **February 2012**.

Contact address for further information on the poster session:

Falk Foundation e.V.  
P.O. Box 6529  
79041 Freiburg/Germany  
Telephone: +49 (0) 761 / 15 14 - 0  
Telefax: +49 (0) 761 / 15 14 - 359  
Web address for submitting poster abstracts:  
<http://www.falkfoundation.com/poster>

For the **first author** of an accepted **poster**, expenses for accommodation (May 3 – 5, 2012) and fees for the scientific program and evening activities will be covered during the Falk Symposium 183. **Travel expenses are not covered.**

## Poster prizes

Three prizes will be awarded for the best presentations.

Prize winners will be presented with a prize certificate and € 1.500,-, € 1.000,- and € 500,- respectively.

Travel expenses will be covered additionally for the first author of prize winning posters.

# List of Speakers, Moderators and Scientific Organizers

## **Dr. Matthieu Allez**

Hôpital Saint-Louis  
Service de Gastroentérologie  
1 Ave. C. Vellefaux  
75010 Paris  
France  
matthieu.allez@sls.aphp.fr

## **Prof. Dr. Christoph Beglinger**

Kantonsspital  
Gastroenterologie  
Petersgraben 4  
4031 Basel  
Switzerland  
beglinger@tmr.ch

## **Dr. Charles N. Bernstein**

University of Manitoba  
Department of Gastroenterology  
804 F-175 McDermot Avenue  
Winnipeg MB R3E 3P4  
Canada  
cbernst@cc.umanitoba.ca

## **Dr. med. Luc Biedermann**

Universitätsspital Zürich  
Gastroenterologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
luc.biedermann@usz.ch

## **Dr. Mathias Chamaillard**

INSERM 1  
rue Prof. A. Calmette  
59021 Lille  
France  
mathias.chamaillard@inserm.fr

## **Prof. Dr. Jean-Frederic Colombel**

Hôpital Claude Huriez  
CHRU Lille  
Gastroenterology & Hepatology  
1, Place de Verdun  
59037 Lille  
France  
jfcolumbel@chru-lille.fr

## **Prof. Dr. Jacques Cosnes**

Hôpital Saint Antoine  
Service de Gastroentérologie  
& Nutrition du Prof. Gendre  
184, Rue du Faubourg St.-Antoine  
75571 Paris  
France  
jacques.cosnes@sat.ap-hop-paris.fr

## **Dr. Silvio Danese**

Istituto Clinico Humanitas  
IRCCS in Gastroenterology  
Via Manzoni, 56  
20089 Rozzano  
Italy  
sdanese@hotmail.com

## **Richard Duerr, M.D.**

University of Pittsburgh  
School of Medicine  
Gastroenterology & Hepatology  
Mezzanine Level, C-Wing-PUH  
200 Lothrop Street  
Pittsburgh PA 15261  
USA  
duerr@pitt.edu

## **Dr. Brian G. Feagan**

University of Western Ontario  
Robarts Research Institute  
LCTRG  
100 Perth Drive  
London ON N6A 5K8  
Canada  
bfeagan@robarts.ca

## **Claudio Fiocchi, M.D.**

Professor of Medicine  
The Cleveland Clinic Foundation  
Pathobiology / NC 20  
9500 Euclid Avenue  
Cleveland OH 44195  
USA  
fiocchc@ccf.org

## **Prof. Dr. Andre Franke**

Klinische Molekularbiologie  
Christian-Albrechts-Universität  
Schittenhelmstrasse 12  
24105 Kiel  
Germany  
a.franke@mucosa.de

**Prof. Dr. Michael Fried**

Universitätsspital Zürich  
Gastroenterologie/Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
michael.fried@usz.ch

**Prof. Dr. Steffen Gay**

Universitätsspital Zürich  
Rheumaklinik und Institut für  
Physikalische Medizin  
Gloriastr. 25  
8091 Zürich  
Switzerland  
steffen.gay@usz.ch

**Prof. Dr. Subrata Ghosh**

University of Calgary  
Foothills Hospital  
Department of Gastroenterology  
1403 29th St. NW  
Calgary AB T2N 2T9  
Canada  
subrata.ghosh@albertahealthservices.ca

**Prof. Dr. Volker Groß**

Innere Medizin II  
Klinikum St. Marien Amberg  
Mariahilfbergweg 7  
92224 Amberg  
Germany  
gross.volker@klinikum-amberg.de

**Prof. Dr. Christopher John Hawkey**

University Hospital  
Queen's Medical Centre  
Dept. of Therapeutics  
Nottingham NG7 2UH  
Great Britain  
cj.hawkey@nottingham.ac.uk

**Hans Herfarth, M.D.**

Associate Professor of Medicine  
University of North Carolina  
Gastroenterology & Hepatology  
4151 Bioinformatics Bldg.  
130 Mason Farm Road  
Chapel Hill NC 27599-7080  
USA  
hherf@med.unc.edu

**Prof. Dr. Derek P. Jewell**

University of Oxford  
The Radcliffe Infirmary  
Gastroenterology Unit  
Nuffield Department of Medicine  
Woodstock Road  
Oxford OX2 6HE  
Great Britain  
derek.jewell@ndm.ox.ac.uk

**Prof. Dr. Arthur Kaser**

University of Cambridge  
Addenbrooke's Hospital  
Division of Gastroenterology  
& Hepatology  
Hills Road  
Cambridge CB2 0QQ  
Great Britain  
ak729@cam.ac.uk

**Prof. Dr. Wolfgang Kruis**

Innere Medizin  
Evang. Krankenhaus Kalk  
Buchforststr. 2  
51103 Köln  
Germany  
kruis@evkk.de

**Prof. Dr. Peter L. Lakatos**

Semmelweis University  
Medical School  
I Department of Medicine  
Koranyi u. 2/a  
1083 Budapest  
Hungary  
kislakpet@bel1.sote.hu

**Dr. Patricia Lepage**

INRA Domaine de Vilvert  
Département d'Hépatogastro-entérologie  
78352 Jouy-en-Josas  
France  
patricia.lepage@jouy.inra.fr

**Prof. Dr. Herbert Lochs**

Universität Innsbruck  
Christoph-Probst-Platz 1  
6020 Innsbruck  
Austria  
elke.moellinger@i-med.ac.at

**Prof. Dr. Pierre Michetti**

La Source-Beaulieu  
Gastro-entérologie  
Avenue Jomini 8  
1004 Lausanne  
Switzerland  
pmichetti@gesb.ch

**Prof. Dr. Christoph Müller**

Universität Bern  
Pathologisches Institut  
Institut für Pathologie  
Murtenstraße 31  
3010 Bern  
Switzerland  
christoph.mueller@pathology.unibe.ch

**Prof. Dr. Ole Haagen Nielsen**

Herlev University Hospital  
Department of Surgery  
Herlev Ringvej 75  
2730 Herlev  
Denmark  
ohni@heh.regionh.dk

**Dr. Laurent Peyrin-Biroulet**

Hôpitaux de Brabois  
C.H.U. de Nancy  
Dept. of Hepato-Gastroenterology  
Allée du Morvan  
54511 Vandoeuvre-Nancy  
France  
peyrin-biroulet@netcourrier.com

**Prof. Dr. Walter Reinisch**

Medizinische Universität Wien  
Gastroenterologie/Hepatology  
Währinger Gürtel 18-20  
1090 Wien  
Austria  
walter.reinisch@meduniwien.ac.at

**Florian Rieder, M.D.**

The Cleveland Clinic Foundation  
Lerner Research Institute  
Department of Pathology, NC22  
9500 Euclid Avenue  
Cleveland OH 44195  
USA  
riederf@ccf.org

**Prof. Dr.Dr. Gerhard Rogler**

Universitätsspital Zürich  
Klinik für Gastroenterologie  
& Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
gerhard.rogler@usz.ch

**William J. Sandborn, M.D.**

Professor of Medicine  
UCSD School of Medicine  
Division of Gastroenterology  
Building UC 303, Room 220  
9500 Gilman Drive  
La Jolla CA 92093  
USA  
wsandborn@ucsd.edu

**Bruce E. Sands, M.D.**

Professor of Medicint  
Mount Sinai School of Medicine  
Department of Gastroenterology  
One Gustave L. Levy Place  
New York NY 10029  
USA  
Bruce.sands@mssm.edu

**R. Balfour Sartor, M.D.**

Professor of Medicine  
University of North Carolina  
School of Medicine  
Gastroenterology & Hepatology  
111 Mason Farm Road  
Chapel Hill NC 27599-7032  
USA  
rbs@med.unc.edu

**Dr. med. Michael Scharl**

Universitätsspital Zürich  
Klinik für Onkologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
michael.scharl@usz.ch

**Prof. Dr. Jürgen Schölmerich**

Klinikum der Johann Wolfgang  
Goethe-Universität Frankfurt  
Theodor-Stern-Kai 7  
60596 Frankfurt  
Germany  
juergen.schoelmerich@kgu.de

**Prof. Dr. Stefan Schreiber**

Innere Medizin I  
Universitätsklinikum  
Schleswig-Holstein, Campus Kiel  
Arnold-Heller-Straße 3 (Haus 6)  
24105 Kiel  
Germany  
s.schreiber@mucosa.de

**Prof. Dr. Jörg-Dieter Schulzke**

Gastroenterologie  
Charité Universitätsmedizin  
Campus Benjamin Franklin (CBF)  
Hindenburgdamm 30  
12203 Berlin  
Germany  
joerg.schulzke@charite.de

**Noah F. Shroyer, Ph.D.**

Assistant Professor of Medicine  
Cincinnati Children's Hospital  
Medical Center  
Developmental Biology  
3333 Burnet Avenue  
Cincinnati OH 45229-3039  
USA  
noah.shroyer@cchmc.org

**Prof. Dr. Eduard F. Stange**

Innere Medizin I  
Robert-Bosch-Krankenhaus  
Auerbachstr. 110  
70376 Stuttgart  
Germany  
eduard.stange@rbk.de

**Prof. Dr. Wolfgang Stremmel**

Innere Medizin IV  
Universitätsklinikum Heidelberg  
Im Neuenheimer Feld 410  
69120 Heidelberg  
Germany  
wolfgang\_stremmel@med.uni-heidelberg.de

**Prof. Dr. Morten H. Vatn**

University of Oslo  
Rikshospitalet  
Medical Clinic of  
Gastroenterology  
0027 Oslo  
Norway  
m.h.vatn@medisin.uio.no

**PD Dr. Stephan Vavricka**

Universitätsspital Zürich  
Klinik für Gastroenterologie  
& Hepatologie  
Rämistrasse 100  
8091 Zürich  
Switzerland  
stephan.vavricka@usz.ch

**PD Dr. Jan Wehkamp**

Innere Medizin I  
Robert-Bosch-Krankenhaus  
Auerbachstr. 110  
70376 Stuttgart  
Germany  
jan.wehkamp@ikp-stuttgart.de

**Joel V. Weinstock, M.D.**

Professor of Medicine  
Tufts-New England  
Medical Center  
Box 233  
750 Washington Street  
Boston MA 02111  
USA  
jweinstock2@tufts-nemc.org

**Prof. Dr. Martin Zeitz**

Gastroenterologie  
Charité Universitätsmedizin  
Campus Benjamin Franklin (CBF)  
Hindenburgdamm 30  
12203 Berlin  
Germany  
martin.zeitz@charite.de

## General Information

**Prior** to the opening of the congress in Basel

Falk Foundation e. V.	Telephone: +49 (0) 761 / 15 14 - 0
Congress Division	Telefax: +49 (0) 761 / 15 14 - 359
Leinenweberstr. 5	E-mail: symposia@falkfoundation.de
P.O. Box 6529	
79041 Freiburg/Br. (Germany)	

## Congress Office

**During** the Falk Symposium 183

Congress Center Basel	Telephone: +41(0)58/206 28 30
Messeplatz 21	Telefax: +41(0)61/681 94 29
4058 Basel	
Switzerland	

### Opening Hours:

Wednesday, May 2, 2012	16.00 – 21.00 h
Thursday, May 3, 2012	8.00 – 16.30 h
Friday, May 4, 2012	7.30 – 18.00 h
Saturday, May 5, 2012	7.30 – 18.30 h

## Congress Fees

Scientific program of the Falk Symposium 183	€ 200,-
Students and residents	€ 100,-

**\*\*\* OR \*\*\***

<b>Day ticket</b>	€ 120,-
Students and residents	€ 60,-

### The congress fees include:

- Welcome Evening on May 2, 2012
- Refreshments during coffee breaks
- Lunch on May 4 and 5, 2012
- A copy of the abstract volume

## Registration

Congress registrations must reach the Falk Foundation e.V. by **March 15, 2012 at the latest**.

Congress fees may be paid by cheque payable to the Falk Foundation e.V. or by bank transfer to Volksbank Freiburg e.G., Germany, Bank No. 68090000, Account No. 1452010, IBAN DE33 6809 0000 0001 4520 10, BIC Genode 61 FR1. Please mark bank transfers with "Falk Symposium 183".

To ensure correct registration, participants are asked to send in their registration and the fee remittance together.

After receipt of registration form, each participant will be provided with confirmation of his registration. On presentation of this confirmation at the Congress Office in Basel participants will receive the congress folder containing name badges, admission tickets and the abstract volume.

In the event of registration cancellations, a handling fee of € 20.- will be deducted from the refund. All participants will receive a written confirmation of attendance at the end of the meeting.

## Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

## Hotel Accommodation

Please send the hotel reservation form by **March 15, 2012 at the latest** to

### **Basel Tourismus**

Incoming Services

Aeschenvorstadt 36

4010 Basel

Switzerland

Tel. +41 (0)61 268 68 60

Fax +41 (0)61 268 68 70

samuel.schibler@basel.com

www.basel.com

The hotel reservation will be confirmed directly by the Basel Tourismus.

## **Congress Report**

The official congress report of the Falk Symposium 183 “Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy” will be published in English in the second half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35.- can be placed at the Congress Office during the congress in Basel.

## **Congress Short Report**

The congress short report of the Falk Symposium 183 “Dealing with our “In-vironment”: New Aspects in IBD Pathogenesis and Therapy” will be published by the Falk Foundation e.V. with number FSK 183 in the second half of 2012.


Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

## **Airport**

International Airport Basel



Falk Foundation  
Dr. Falk Pharma



*Where medicine  
and pharmaceuticals meet –  
a tried and trusted link*

### **Innovative Drugs**

for bowel and liver diseases

Modern formulations and specially designed delivery systems ensure targeted release of the active drug

### **Scientific Dialogue**

in the interest of therapeutic progress

Falk Symposia and Workshops

nearly 250, attended by more than 100,000 participants from over 100 countries since 1967

Continuing medical education seminars

over 14,000, attended by more than one million physicians and patients in Germany alone


Comprehensive literature service for healthcare professionals and patients

with more than 200 publications

**[www.falkfoundation.org](http://www.falkfoundation.org)**

**[www.dralfalkpharma.com](http://www.dralfalkpharma.com)**

Leinenweberstr. 5 79108 Freiburg Germany Tel +49 (0)761/1514-0 Fax +49 (0)761/1514-321 Mail [zentrale@dralfalkpharma.de](mailto:zentrale@dralfalkpharma.de)



## General Information:

FALK FOUNDATION e.V.



Leinenweberstr. 5  
79108 Freiburg  
Germany

Congress Division

Telephone: +49(0)761/1514-0

Telefax: +49(0)761/1514-359

E-mail: [symposia@falkfoundation.de](mailto:symposia@falkfoundation.de)

[www.falkfoundation.org](http://www.falkfoundation.org)